Patents by Inventor Cornelius Kloeck

Cornelius Kloeck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of tissue transglutaminase activation in disease
    Patent number: 10010541
    Abstract: Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activity of TG2 associated with inflammatory disorders, which disorders may include, without limitation, sepsis, ischemic reperfusion injury, renal fibrosis, and the like.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: July 3, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Chaitan Khosla, Thomas DiRaimondo, Cornelius Kloeck
  • MODULATION OF TISSUE TRANSGLUTAMINASE ACTIVATION IN DISEASE
    Publication number: 20170266198
    Abstract: Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activation of TG2 associated with enteric inflammatory disorders, which disorders may include celiac disease, irritable bowel syndrome, Crohn's Disease, dermatitis herpetiformis, and the like. In other embodiments of the invention, methods are provided for reducing undesirable paracellular transport in enteric tissues, in particular the paracellular transport of molecules greater than about 500 mw, e.g. peptides, including without limitation immunogenic gluten peptides.
    Type: Application
    Filed: April 12, 2017
    Publication date: September 21, 2017
    Inventors: Thomas DiRaimondo, Xi Jin, Cornelius Kloeck, Chaitan Khosla
  • Modulation of Tissue Transglutaminase Activation in Disease
    Publication number: 20160339012
    Abstract: Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activity of TG2 associated with inflammatory disorders, which disorders may include, without limitation, sepsis, ischemic reperfusion injury, renal fibrosis, and the like.
    Type: Application
    Filed: January 29, 2015
    Publication date: November 24, 2016
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR
    Inventors: Chaitan Khosla, Thomas DiRaimondo, Cornelius Kloeck
  • Modulation of Tissue Transglutaminase Activation in Disease
    Publication number: 20140322278
    Abstract: Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activation of TG2 associated with enteric inflammatory disorders, which disorders may include celiac disease, irritable bowel syndrome, Crohn's Disease, dermatitis herpetiformis, and the like. In other embodiments of the invention, methods are provided for reducing undesirable paracellular transport in enteric tissues, in particular the paracellular transport of molecules greater than about 500 mw, e.g. peptides, including without limitation immunogenic gluten peptides.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 30, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Thomas DiRaimondo, Xi Jin, Cornelius Kloeck, Chaitan Khosla